Literature DB >> 27442271

Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development.

Kaspar Rufibach1, Hans Ulrich Burger2, Markus Abt2.   

Abstract

Bayesian predictive power, the expectation of the power function with respect to a prior distribution for the true underlying effect size, is routinely used in drug development to quantify the probability of success of a clinical trial. Choosing the prior is crucial for the properties and interpretability of Bayesian predictive power. We review recommendations on the choice of prior for Bayesian predictive power and explore its features as a function of the prior. The density of power values induced by a given prior is derived analytically and its shape characterized. We find that for a typical clinical trial scenario, this density has a u-shape very similar, but not equal, to a β-distribution. Alternative priors are discussed, and practical recommendations to assess the sensitivity of Bayesian predictive power to its input parameters are provided.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian predictive power; conditional power; prior distribution; probability of technical success

Mesh:

Year:  2016        PMID: 27442271     DOI: 10.1002/pst.1764

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  5 in total

1.  A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials.

Authors:  Kevin Kunzmann; Michael J Grayling; Kim May Lee; David S Robertson; Kaspar Rufibach; James M S Wason
Journal:  Am Stat       Date:  2021-04-22       Impact factor: 8.710

2.  Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.

Authors:  Maria M Ciarleglio; Christopher D Arendt
Journal:  Trials       Date:  2017-02-23       Impact factor: 2.279

Review 3.  The Bayesian Design of Adaptive Clinical Trials.

Authors:  Alessandra Giovagnoli
Journal:  Int J Environ Res Public Health       Date:  2021-01-10       Impact factor: 3.390

4.  Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials.

Authors:  Kevin Kunzmann; Michael J Grayling; Kim May Lee; David S Robertson; Kaspar Rufibach; James M S Wason
Journal:  Stat Med       Date:  2022-01-13       Impact factor: 2.497

5.  How large should the next study be? Predictive power and sample size requirements for replication studies.

Authors:  Erik W van Zwet; Steven N Goodman
Journal:  Stat Med       Date:  2022-04-08       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.